Exactech, Inc. (NASDAQ:EXAC)

CAPS Rating: 5 out of 5

The Company designs, manufactures, markets and distributes orthopaedic implant devices including knee, hip, shoulder and ankle joint replacement systems, bone allograft materials, surgical instrumentation, and bone cement and accessories.

Results 21 - 28 of 28 : « Previous 1 2

Recs

0
Member Avatar YellowBill (< 20) Submitted: 1/10/2008 3:29:24 PM : Outperform Start Price: $22.23 EXAC Score: -21.13

Boomers are getting older. Demand for Exactech products grows at a steady rate as Boomers age.

Recs

0
Member Avatar lareineivre (75.69) Submitted: 12/30/2007 2:48:23 AM : Outperform Start Price: $20.83 EXAC Score: -13.18

Favorable risk / reward profile. Comparative analysis:
http://f1.grp.yahoofs.com/v1/8EF3R8IApDlbI1SUEwj9ACPoO-N506V3BymU7tTVdt21_4PxNLCn-oJ6KY_K8iQ5Z-yn652fM-b9S1MpHcVrFg/VOps/VOps%2007.11.30.xls

Recs

0
Member Avatar JCash22 (85.64) Submitted: 12/1/2007 3:46:21 AM : Outperform Start Price: $19.17 EXAC Score: -6.02

As we get older, so do our bones.

Recs

0
Member Avatar PIcolano (< 20) Submitted: 11/6/2007 12:06:00 PM : Outperform Start Price: $21.66 EXAC Score: -14.71

Interesting metrics - let's see where it goes...

Recs

0
Member Avatar johnnymack91362 (75.83) Submitted: 10/30/2007 1:58:11 PM : Outperform Start Price: $17.85 EXAC Score: +3.75

medical implants for knees,hips and shoulders. nice revenue trajectory.

Recs

1
Member Avatar StockBoxChandler (< 20) Submitted: 10/7/2007 2:05:06 PM : Outperform Start Price: $15.75 EXAC Score: +15.27

Currently there are 500,000 knee operations per year in the United States. In 25 years that number is expected to grow to 3,000,000. Exactech is a orthopedic implant manufacturer that is well positioned to take advantage of such growth. Granted there are big players in the market such as Biomet, Stryker and Johnson & Johnson, but with 41 percent insider ownership and an increasingly strong sales force and product pipeline Exactech is well positioned to compete on the largest stage. Currently, Exactech is cheaply priced compared to much larger competitors that don't share Exactech's growth prospects. Also, with just a 180 million dollar market cap, very few analysts and institutions follow Exactech. As the company grows increases in analyst following could buoy the stock price further bring better returns to Exactech's shareholders.

Here is some pretty good research on Exactech: http://stockboxfinancial.com/stockbox_picks/stockboxpick_exac.pdf

Recs

0
Member Avatar Fedyzer (63.80) Submitted: 8/12/2007 5:17:00 PM : Outperform Start Price: $15.90 EXAC Score: +10.42

an artificial joint that doesn't wear out. nuff said.

Recs

0
Member Avatar bplatt03446 (< 20) Submitted: 1/23/2007 3:13:00 PM : Outperform Start Price: $16.15 EXAC Score: +5.46

growth in their target market

Results 21 - 28 of 28 : « Previous 1 2

Featured Broker Partners


Advertisement